trial
as of 2026-07-01A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
NCTId NCT06388551
at a glance
Phase 1 · Unknown
Enrollment 60 (estimated)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-03-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Unknown
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2024-05-10
Primary completion
2025-03-30
Eligibility
ALL · 18 Years · 45 Years
Interventions & indications
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Sites
1 total
Shanghai, China
Facts & assertions
4 sourced
Enrollment
60
Phase
PHASE1
Primary Completion Date
2025-03-30
Status
UNKNOWN
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication